Introduction

Senescence affects organisms by impairing cellular functions and increasing disease risk. Recent advances in aging research aim to not only extend lifespan but also improve healthspan—the period lived with minimal disease. Seragon Biosciences, a biotech company focused on aging interventions, tested SRN-901, an oral drug candidate designed to combine mTOR inhibition, autophagy activation, NAD+ enhancement and senolytic stimulation. In a comprehensive preclinical study involving over 300 mice, SRN-901 delivered remarkable results, opening new directions for targeted therapies against age-related decline.

Key Findings

• SRN-901 extended remaining lifespan by 34.4% in middle-aged mice, outperforming rapamycin.
• Treated mice showed a 70% increase in activation of longevity genes Sirt6, Parp1 and Sod2.
• Anti-longevity markers Igf1r, Ccl4 and Il6 decreased by 40% on average.
• Physical endurance more than doubled, with treated mice covering over 50% of young counterparts’ treadmill distance.

Study Design and Methods

The research team conducted a multi-year experiment from 2021 to 2024, monitoring over 300 middle-aged mice. Animals received oral doses of SRN-901 or control vehicle and underwent periodic assessments including transcriptomic and proteomic analysis, RNA sequencing and physiological tests. Machine-learning-assisted bioinformatics integrated data from metabolism, immune function and programmed cell death pathways to build a comprehensive profile of drug effects on aging phenotypes.

Mechanisms of Action

SRN-901’s formulation targets four major longevity pathways: mTOR inhibition to slow cell growth and maintenance; autophagy activation for cellular cleanup; NAD+ enhancement to support energy metabolism; and senolytic stimulation to clear damaged cells. By acting on multiple targets, the compound addresses interconnected molecular hallmarks of aging, resulting in synergistic improvements beyond single-pathway interventions.

Healthspan Benefits

Beyond lifespan extension, SRN-901 improved tissue metabolic markers such as gamma-glutamyl glutamine and glutathione, a native antioxidant. Researchers observed reductions in blood glucose and uric acid, indicating better metabolic health. Cognitive tests revealed potential protection against dementia, and frailty scores improved, suggesting sustained muscle strength and resilience in treated mice.

Metabolic and Molecular Markers

Comprehensive bioinformatics analysis highlighted activation of DNA repair, signal transduction, immune response and programmed cell death pathways. Longevity gene expression resembled profiles of young mice, while pro-aging markers diminished. These molecular changes correlate with functional benefits, showcasing SRN-901’s capacity to recalibrate aging-associated networks at the genetic and metabolic levels.

Translational Potential and Next Steps

Seragon Biosciences holds patents from Harvard University, Mayo Clinic and Scripps Research, and intends to advance SRN-901 toward clinical trials. In the interim, RESTORIN, a nutraceutical developed from this research, may offer initial benefits. The team plans to publish supplementary data in the coming months and expand collaborations across academic and industry partners to accelerate human applications.

Conclusion

SRN-901 represents a promising multi-target approach to aging intervention, showing significant lifespan and healthspan gains in mice. By merging advanced bioinformatics with robust preclinical data, Seragon Biosciences paves a path toward therapies that extend disease-free years of life. Future studies will determine its safety and efficacy in humans, marking an important step in longevity science.

Key points

• SRN-901 extended remaining lifespan by 34.4% in middle-aged mice and improved physical endurance.
• Treatment restored youthful gene expression in key longevity genes (Sirt6, Parp1, Sod2) and reduced anti-longevity markers.
• Integrated bioinformatics analysis showed enhancements in metabolic and immune function pathways, suggesting significant healthspan benefits.